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ABSTRACT 
Background: Chronic norovirus infection is an emerging challenge in the immunocompromised 
host, in whom it may be asymptomatic or present as chronic diarrhea. The mechanisms of 
diarrhea in chronic norovirus infection are not well understood, but in analogy to Gardia lamblia 
and rotavirus infections, secondary lactose maldigestion (LM) might be implicated. 
Methods: Adult renal transplant recipients (RTRs) who had symptomatic chronic norovirus 
infection with diarrhea were asked to participate in this prospective parallel cohort study. RTRs 
with otherwise unexplainable chronic diarrhea but absent infection served as control group. In 
both groups, a lactose hydrogen breath test (LHBT) and a lactose tolerance test (LTT) were 
performed after exclusion of primary LM by a negative lactase gene test. 
Results: Of approximately 800 patients in the cohort of RTRs at our institution, 15 subjects were 
included in the present study. Of these, 7 had chronic symptomatic norovirus infection with 
diarrhea (noro group) and 8 had diarrhea in the absence of norovirus (control group). LHBT and 
LTT were positive in all 7 patients (100%) in the noro group, whereas only 1 of 8 patients 
(12.5%) in the control group had a positive test. Thus, secondary LM was highly prevalent in the 
noro compared to the control group with an odds ratio of 75.0 (95% CI 2.6, 2153, p=0.01). 
Conclusions: This is the first report showing a positive association of chronic norovirus infection 
and secondary LM. Further studies with larger patient numbers and longer follow-up are needed 
to test a causative relationship between both entities. 
 
Key Words: Chronic norovirus infection, chronic diarrhea, renal transplant recipients, lactose 
maldigestion  
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Introduction 
Norovirus, a single-stranded RNA virus of the Caliciviridae family, is a human enteric 
pathogen that is 1 of the leading causes of acute gastroenteritis, presenting as self-limited disease 
of short duration in immunocompetent subjects.1-3 However, chronic norovirus infection is an 
emerging challenge in the immunocompromised host such as leukemia patients or solid organ 
transplant recipients, in whom the virus may persist and present as chronic diarrhea and diffuse 
abdominal discomfort, and may even be associated with kidney transplant dysfunction.4-8 
Norovirus accounts for 17-26% of severe posttransplant diarrhea in renal transplant 
recipients.5,6,9 Norovirus related diarrhea is associated with the greatest weight loss compared to 
other causes of diarrhea.5,9 Histologically, signs of chronic intestinal inflammation are present.4,5 
Until now, the mechanisms of diarrhea in case of chronic norovirus infection are not well 
understood, and treatment options are limited. 
Lactose is a disaccharide and a frequent constituent of a typical Western-type diet. Lactose 
maldigestion (LM) refers to inefficient cleavage of lactose in the small intestine, resulting in 
lactose malabsorption and fermentation of lactose by the colonic microbiota. In contrast, lactose 
intolerance (LI) is defined as the development of symptoms after lactose challenge in individuals 
with LM.10 LM is a frequent condition, affecting more than 50% of all individuals worldwide 
and should be regarded a variant of human intestinal physiology.11 Primary LM is typically 
associated with the CC polymorphism of the -13910 locus of the lactase (LCT) gene.12 In 
contrast, secondary LM can develop in many intestinal inflammatory conditions; however, which 
specific conditions will lead to LM as well as mechanistic aspects, have not been sufficiently 
clarified. 
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In a prospective study in children with acute gastroenteritis, a significant proportion was found to 
have LM, which was most commonly associated with rotavirus infection.13 Secondary LM has 
also been reported in patients with Giardia lamblia infections, and the latter were shown to alter 
the cellular glycocalyx resulting in alterations of brush border disaccharidase enzymes.14,15 In 
line with these findings we suspect a similar mechanism in symptomatic patients with chronic 
norovirus infections. The objective of this study was therefore to determine the prevalence of 
secondary LM in patients with chronic norovirus infection. 
 
Materials and Methods 
Subjects 
Between July 2013 and March 2015 all adult renal transplant recipients (RTRs) at the 
University Hospital Zürich who had symptomatic chronic norovirus infection with diarrhea were 
asked to participate in this prospective parallel cohort study. According to the WHO-approved 
definition of diarrhea we chose the cut-off of 3 or more bowel movements per day for more than 
4 weeks as indicative of chronic diarrhea. Chronic norovirus infection was proven by positive 
polymerase chain reaction (PCR) analysis of recent stool samples, whereas chronic virus 
shedding was defined as more than 2 PCR positive samples at an interval of at least 1 month. 
Concomitant viral (ie cytomegalovirus), bacterial (ie Salmonella spp., Campylobacter spp., 
Shigella spp., and C.difficile) and parasitic (Gardia lamblia, Microspora spp., and Cryptospora 
spp.) intestinal infections were excluded by negative stool PCR analyses, stool cultures, and 
direct microscopic stool examinations, respectively. Furthermore, CMV viremia was excluded 
by PCR technique. Main exclusion criterion for the present study was a concomitant intestinal 
infection (other than norovirus), and primary LM which was previously excluded by absence of 
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the CC genotype of the DNA variant -13910 T/C upstream in the LCT gene. Subjects with a 
proven galactosemia or those requiring a low galactose diet were also excluded. RTRs with 
otherwise unexplainable chronic diarrhea but absent norovirus or another intestinal infection, and 
negative LCT gene test served as control group. In both groups, a lactose hydrogen breath test 
(LHBT) and a lactose tolerance test (LTT) were performed in all eligible RTRs (Figure 1). LM 
was diagnosed with a positive LHBT and/or a positive LTT.  
Written informed consent was obtained from all patients included in the study. The study 
was approved by the local Ethics committee (KEK-ZH 2012-0473) and is registered at 
ClinicalTrials.gov (identifier: NCT01840891). 
 
 Lactose H2 breath test (LHBT) 
The LHBT was performed according to the Rome consensus conference.16 After an 
overnight fast of at least 12 hours, a basal breath sample was collected. No individual showed a 
baseline hydrogen (H2) level above 20 ppm (not shown). RTRs were allowed to drink water and 
follow their usual medication regimen during the entire examination. After collecting the 
baseline sample, RTRs were given 25 g of lactose dissolved in 250 ml of water to drink. Orange 
flavored lactose powder (or milk powder) was provided with the AlveoSampler™ Lactose Kit 
(Quintron Instrument Co., Milwaukee, WI, USA). Samples of end expiratory breath were then 
collected at 30, 60, 90 and 120 minutes after the oral lactose load to measure the concentration of 
H2, which was considered significantly increased and indicative of LM when exceeding 20 
ppm.16,17 During the test, RTRs were allowed to engage in normal activities, but were kept 
fasting except for water consumption which was permitted throughout the examination. The test 
was performed in a well-ventilated room free of fresh painted walls or objects and with no 
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evidence of any organic solvents or cigarette smoke. The breath samples were collected in 
specially constructed bags, which are provided along with the instrument. Exhaled breath H2 was 
measured on a Model 12i Microlyser (Quintron Instrument Co., Milwaukee, WI, USA). The 
number of loose bowel motions and flatulence during the test were also documented. 
 
Lactose tolerance test (LTT) 
Following the above mentioned oral administration of 25 g lactose, capillary blood 
glucose levels were measured at 0, 60, and 120 minutes, by using a glucometer (Ascensia 
Contour, Bayer AG, Leverkusen, Germany). An increase of blood glucose by less than 1.1 
mmol/l in conjunction with the development of abdominal symptoms was defined diagnostic for 
LI.17 
 
Statistical analysis 
Baseline data are reported as median (interquartile range, IQR), or numbers (percentages) 
as appropriate. Differences in baseline characteristics and between the 2 study groups were 
estimated using the Mann-Whitney U test for continuous variables and the χ2 test for categorical 
variables. Values of exhaled breath hydrogen concentrations and blood glucose are presented as 
median (interquartile range, IQR). Differences of these values between different points in time 
were calculated using the paired sample Wilcoxon signed rank test. P-values of all outcomes 
were 2-sided; values less than 0.05 were considered to indicate statistical significance. All 
statistical analyses were performed using IBM SPSS Statistics for Windows, version 22 (IBM 
Corporation, Armonk, NY). 
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Results 
Of approximately 800 patients in the cohort of adult RTRs at the University Hospital 
Zürich, 22 individuals were identified with chronic diarrhea, 15 of which could be included in 
the present study (Figure 1). Four individuals were excluded due to primary LM in line with an 
expected frequency of primary LM in Switzerland of 20-40%11 Seven of these 15 individuals had 
chronic symptomatic norovirus infection with diarrhea with the genotype G2.4 (noro group), and 
8 patients had diarrhea in the absence of norovirus infection and served as control group. 
Baseline characteristics of the subjects in both groups are shown in Table 1, and laboratory data 
are summarized in Table 2. Cytomegalovirus high risk constellation (CMV donor/recipient 
serostatus D+/R-) was significantly more prevalent in the control group (p=0.013). However, the 
onset of diarrhea before study inclusion was significantly earlier in the noro group (p=0.038). 
Other variables, such as age, sex, mode and dose of immunosuppression, prevalence of diabetes 
mellitus, and laboratory values were comparable in both groups. At the moment of the testing, no 
patient was treated with antibiotics, and CMV PCR was negative in all patients. As part of the 
clinical routine diagnostic in transplanted patients with chronic diarrhea, 6 patients (85.7%) in 
the norovirus group had a colonoscopy. In all patients, the histology showed chronic 
inflammatory changes. CMV-colitis was specifically excluded with histology and 
immunohistochemistry of biopsy specimens. The final diagnosis of chronic diarrhea in those 
patients without evidence of norovirus infection was mycophenolate-associated colitis in 3 and 
unknown etiology or diabetes mellitus in 5 cases. 
   
In the noro group, all patients had a positive LHBT. In the control group, only 1 patient (12.5%) 
had a positive test (Table 3). Accordingly, the increase of the median exhaled H2 content 
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between baseline (7.0 (2.0, 11.0) ppm) and 120 minutes after lactose ingestion (35.5 (10.0, 66.2) 
ppm) in the noro group was significant (p=0.043) (Figure 2). By contrast, in the control group H2 
values only a minor, nonsignificant increase between baseline (4.0 (1.2, 6.0) ppm) and after 
lactose exposure was observed (9.0 (4.0, 16.2) ppm) (p=0.063) and all values remained below 
the threshold of 20ppm. 
Analogously, LTT was positive in all patients in the noro group, whereas only the above 
mentioned patient in the control group had a positive test (Table 3). However, in both groups the 
increase of blood glucose between baseline and 60 min after lactose ingestion was significant 
(Figure 3), although the difference was more pronounced in the control group (baseline 5.3 (5.1, 
6.6) mmol/l; after 60 min 7.9 (5.9, 8.5) mmol/l) (p=0.017) compared to the noro group (baseline 
5.4 (4.8, 5.5) mmol/l; after 60 min 6.4 (5.7, 7.0) mmol/l) (p=0.046). 
In all but 1 patient of the noro group, there were abdominal symptoms after lactose ingestion 
(diarrhea, n=2; bloating, n=3; combination of diarrhea and bloating, n=1). In the control group, 
no patient reported abdominal symptoms (Table 3). The patient in the control group with positive 
LHBT and LTT denied any symptoms after lactose ingestion. 
Based on both tests, secondary LM was highly prevalent in the noro group compared to the 
control group with an odds ratio of 75.0 (95% CI 2.6, 2153), p=0.01. Likewise, for secondary LI 
(defined as LM with symptoms), the odds ratio was 73.7 (95% CI 2.6, 2120), p=0.01 (Table 3). 
 
Discussion 
Chronic norovirus infection is an emerging challenge in the immunocompromised host, in 
whom it may present as chronic diarrhea. The aim of the present study was to investigate 
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whether secondary LM can contribute to diarrhea in patients with chronic norovirus shedding. 
This is the first report showing a positive association of chronic norovirus infection in RTRs and 
secondary LM, suggesting a causative relationship between both entities. In addition, LI was 
highly prevalent, and diarrhea lasted substantially longer in RTRs with symptomatic chronic 
norovirus infection. Thus, secondary LM due to chronic norovirus infection could possibly be 
another cause of chronic diarrhea beside drug-induced diarrhea (eg mycophenolate) in 
immunosuppressed patients. Schorn et al found in their case series of RTRs with chronic 
norovirus infection, that the intensity of immunosuppression correlated with diarrheal symptoms 
but not with viral shedding.6 Thus, immunosuppression dosage is maybe the most important risk 
factor for chronic norovirus infection. Therefore, we generally follow a stepwise approach with 
first reducing the dosage of mycophenolate because of the possibility of a coincident 
mycophenolate toxicity contributing to the chronic diarrhea, followed by reduction of the 
calcineurin-inhibitor dosage and attempt to taper/stop prednisone therapy. In our study, 
immunosuppressant dosage was similar in both groups in our study. However, lymphocyte 
counts were significantly lower in the noro group.  
In general, endoscopy was performed for ongoing chronic diarrhea to rule out other conditions. 
However, colonoscopy was not an inclusion criterion in this study, although most of the patients 
had the procedure performed prior to study inclusion. Our standard procedure in RTR’s with 
chronic diarrhea is CMV-PCR in blood, stool cultures for bacteria including Clostridium difficile 
and Clostridium toxin detection, PCR analysis of stool specimens for norovirus, and microscopy 
for parasites such as Microsporidium and Cryptosporidium. If the tests are negative, and the 
diarrhea persists, we first reduce the mycophenolate doses or change to enteric coated 
mycophenolic acid and try to reduce the cumulative immunosuppressive dosage according to the 
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immunological risk. If the diarrhea still persists, patients underwent a colonoscopy to look for 
other causes such as CMV colitis or mycophenolate toxicity.   
LHBT is a standard diagnostic test for LM in clinical practice. However, 2 potential limitations 
should be mentioned: Small intestine bacterial overgrowth (SIBO) with lactose fermentation and 
H2 production in the small intestine could potentially lead to a false positive LHBT. However, 
SIBO and LM can be distinguished, since the resulting H2 peak will be early in the former (small 
bowel peak), but delayed and more prominent in the latter (colonic peak).18 Furthermore, in a 
variable fraction of individuals (2-43%, <10% in most studies) the bowel flora does not produce 
H2, leading to a false negative LHBT.16 
Limitations of LTT include fluctuations of blood sugar levels for instance due to impaired 
glucose tolerance, diabetes or other influences.19 The small increase in blood sugar levels 
required for a positive test will thus result in an inferior sensitivity and specificity of LTT, 
therefore this test is not recommended as a routine diagnostic test for LM.10,20 However, since 
limitations of LHBT and LTT are largely nonoverlapping these tests can complement each other. 
In our study we found a perfect agreement of both tests regarding LM, arguing for the validity of 
our results. 
Importantly, in the noro group but not in the control group, patients reported symptoms after 
lactose ingestion, suggesting that patients with chronic norovirus infection in fact suffer from LI. 
For most individuals with LM, a blinded challenge with 25 g of lactose does not result in any 
symptoms.21 Therefore, symptoms after lactose ingestion in individuals with LM are likely due 
to the concomitant presence of visceral hypersensitivity, for instance due to irritable bowel 
syndrome (IBS). This was also suggested in a blinded controlled study where a challenge with 20 
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g lactose resulted in typical symptoms in 47% of patients with IBS but only in 22% of control 
patients.22 Postinfectious IBS has been reported as a complication of viral gastroenteritis.23 Our 
patients were not formally tested for the presence of IBS. However, our data suggest that visceral 
hypersensitivity can also complicate chronic norovirus infection. 
Secondary LM has been reported in patients with intestinal inflammation due to other chronic 
inflammatory conditions including Crohn’s disease.24,25 In a rat model of mucositis, lactose 
digestion was severely reduced, along with downregulation of lactase mRNA and protein levels, 
while glucose absorption remained intact.26 In this study, other intestinal disaccharidases were 
also downregulated, suggesting that lactase might be a marker for a more general derangement of 
digestive enzymes. Clearly, an isolated downregulation of lactase does not explain chronic 
diarrhea in norovirus infected patients since most individuals with primary LM are free of 
symptoms. Therefore, further mechanistic studies regarding the expression of lactase levels and 
other disaccharidases are clearly needed. 
We are conscious that our study has several limitations. First, the sample size is small which is 
due to the low prevalence of symptomatic chronic norovirus infection. Secondly, since our study 
focused on RTRs the results might not be extrapolated to other immunocompromised disease 
states in which chronic norovirus infection is a relevant concern.8 Thirdly, the investigators were 
not blinded for the results of norovirus PCR before lactose tolerance testing and no blinded 
placebo control was done as suggested by an NIH conference addressing LI.27 Thus, placebo 
effects for the development of symptoms cannot be totally excluded. Finally, no additional tests 
regarding intestinal malabsorption were performed and our study does not provide a 
comprehensive information regarding all aspects of intestinal malfunction in norovirus infection.  
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Conclusion 
This is the first study to show a positive association between chronic norovirus infection 
and secondary LM in RTRs. Future studies should address whether a lactose-reduced diet might 
be of therapeutic benefit. 
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Figure 1. Study flow chart 
 
LHBT, lactose H2 breath test; LTT, lactose tolerance test 
 
Figure 2. Lactose H2 breath test 
 
Exhaled H2 content before and after ingestion of 25 g lactose 
 
Figure 3. Lactose tolerance test 
 
Serum glucose before and after ingestion of 25 g lactose 
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Figure 1 
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Figure 2 
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Figure 3 
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Table 1. Baseline characteristics 
 
 
Control group 
(n=8) 
Noro group 
(n=7) 
p-
value 
Age, years 52 (47, 60) 50 (34, 56) 0.46 
Male sex 6 (75) 4 (57) 0.46 
BMI, kg/m
2 24.8 (23.2, 26.5) 22.2 (17.0, 24.4) 0.09 
Time since transplantation, years 2 (1-4) 6 (2-9) 0.23 
RTx/RPTx 7/1 5/2 0.44 
Immunosuppression, n (median daily 
dose; through level) 
- Prednisone 
- Azathioprine 
- Mycophenolate 
- Ciclosporine 
- Tacrolimus 
 
 
2 (5 mg) 
0 
8 (1250 mg) 
1 (150 mg; 51 µg/l) 
7 (4 mg; 7.3 µg/l) 
 
 
1 (10 mg) 
1 (150 mg) 
6 (1000 mg) 
1 (90 mg; 50 µg/l) 
6 (3.3 mg; 6.8 µg/l) 
 
 
0.87 
0.69 
0.23 
0.78 
0.85 
CMV risk constellation 
- High (D+/R-) 
- Intermediate (D+/R+ or D-/R+) 
- Low (D-/R-) 
 
4 (50) 
2 (25) 
2 (25) 
 
0 (0) 
7 (100) 
0 (0) 
 
 
0.013 
CMV PCR negative 
Duration of diarrhea, weeks 
8 
13 (6-22) 
7 
35 (24-46) 
0.46 
0.038 
Diabetes mellitus 3 (38) 2 (12) 0.31 
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Data are presented as median (interquartile range), or numbers (percent). BMI, body mass index; 
CMV, cytomegalovirus; PCR, polymerase chain reaction; RTx, renal transplantation; RPTx, 
combined renal-pancreatic transplantation  
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Table 2. Baseline laboratory values 
 Control group 
(n=8) 
Noro group 
(n=7) 
p-
value 
Hemoglobin, g/l 135 (118, 147) 122 (106, 133) 0.46 
Leucocytes, G/l 6.1 (4.8, 6.9) 4.1 (4.0, 6.0) 0.12 
Lymphocytes, G/l 1.42 (0.93-1.61) 1.00 (0.57-1.05) 0.041 
Alanine transaminase, U/l 20 (14, 24) 22 (17, 37) 0.28 
Alkaline phosphatase, U/l 56 (55, 81) 80 (55, 92) 0.71 
Estimated glomerular filtration rate*, 
ml/min/1.73 m2 
48 (43, 58) 43 (40, 48) 0.40 
Potassium, mmol/l 4.1 (4.0, 4.1) 4.4 (3.8, 4.8) 0.40 
Sodium, mmol/l 140 (138, 140) 141 (139, 143) 0.28 
Glucose, mmol/l 5.4 (4.8, 6.0) 5.1 (5.0, 5.5) 0.69 
C-reactive protein, mg/l 0.9 (0.6, 1.5) 0.4 (0.3, 0.5) 0.054 
 
Data are presented as median (interquartile range). * CKD-EPI equation.  
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Table 3. Test results of LHBT and LTT 
 Noro group (n=7) Control group (n=8) 
LHBT / LTT positive 7 (100)* 1 (12.5)* 
GI symptoms after lactose 6 (85.7)# 0 (0) # 
 
Values are displayed in n (%). * p=0.001; # p=0.057. 
GI, gastrointestinal; LHBT, lactose H2 breath test; LTT, lactose tolerance test 
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